




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 405/12, A61K 31/445, C07D 307/87, 311/76	A1	(11) International Publication Number: WO 99/25714 (43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/IB98/01704 (22) International Filing Date: 26 October 1998 (26.10.98) (30) Priority Data: PCT/IB97/01466 19 November 1997 (19.11.97) IB (71) Applicant (for JP only): PFIZER PHARMACEUTICALS INC. [JP/JP]; Mitsui Building, 1-1, Nishi-shinjuku 2-chome, Shinjuku-ku, Tokyo 163 (JP). (71) Applicant (for all designated States except JP US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): SATAKE, Kunio [JP/JP]; 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS



(I)

(57) Abstract

This invention provides a compound of formula (I) and its pharmaceutically acceptable salts, wherein R^1 is C_1-C_6 alkyl; R^2 is hydrogen, C_1-C_6 alkyl, halo C_1-C_6 alkyl or phenyl; R^3 is hydrogen or halo; R^4 and R^5 are independently hydrogen, C_1-C_6 alkyl or halo C_1-C_6 alkyl; and n is one, two or three. These compounds are useful as analgesics or anti-inflammatory agents, or in the treatment of cardiovascular diseases, allergic disorders, angiogenesis, CNS disorders, emesis, gastrointestinal disorders, sunburn, urinary incontinence, or diseases, disorders or adverse conditions caused by *Helicobacter pylori*, or the like, in a mammalian subject, especially humans. Intermediates for preparation of the compounds of formula (I) are also disclosed.